Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00001398 · ClinicalTrials.gov registry record · Phase 1
Stem Cell Factor Medication for Aplastic Anemia
A Phase 1 study of Aplastic Anemia and Pancytopenia, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT00001398 is a Phase 1 study of Aplastic Anemia and Pancytopenia that has completed, run by National Heart, Lung, and Blood Institute (NHLBI). The registered enrollment target is 40 participants, roughly in line with the 41-participant average among 23 other Aplastic Anemia trials with a reported enrollment target. The trial reports 1 study location across 1 state.
The verdict
NCT00001398, a Phase 1 study of Aplastic Anemia and Pancytopenia, has completed, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
This trial, sponsored by Amgen, Inc., which produces the recombinant methionyl human stem cell factor (r-metHuSCF), also involves two other institutions. The primary objective is determination of the safety of administering multiple doses of r-metHuSCF in the setting of acquired aplastic anemia and evaluation of the effect of r-metHuSCF on peripheral blood counts. Potential effects of r-metHuSCF on frequency of need for red cell or platelet transfusions and on bone marrow morphology/cellularity will also be evaluated.
Conditions Studied
Interventions
- DRUG Recombinant Methionyl Human Stem Cell Factor (r-metHuSCF)
Study Locations (1)
Maryland
- National Heart, Lung and Blood Institute (NHLBI) - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 1993-10 |
| Est. Completion | 2002-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00001398
The ClinicalTrials.gov registry entry for NCT00001398 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 41-participant average among 23 other Aplastic Anemia trials with a reported enrollment target. The listed sponsor is National Heart, Lung, and Blood Institute (NHLBI), which has 501 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Aplastic Anemia appearing as the primary indexed condition, and to 1 intervention - of which Recombinant Methionyl Human Stem Cell Factor (r-metHuSCF) is the first listed.
NCT00001398 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT00001398 about?
NCT00001398 is a clinical study titled "Stem Cell Factor Medication for Aplastic Anemia". This trial, sponsored by Amgen, Inc., which produces the recombinant methionyl human stem cell factor (r-metHuSCF), also involves two other institutions. The primary objective is determination of the safety of administering multiple doses of r-metHuSCF in the setting of acquired aplastic anemia and ...
What is the current status of trial NCT00001398?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 1993-10. Estimated completion is 2002-06.
What conditions does trial NCT00001398 study?
This clinical trial studies the following conditions: Aplastic Anemia, Pancytopenia.
What interventions are being tested in trial NCT00001398?
The interventions under investigation include: Recombinant Methionyl Human Stem Cell Factor (r-metHuSCF) (DRUG).
Who is sponsoring clinical trial NCT00001398?
This trial is sponsored by National Heart, Lung, and Blood Institute (NHLBI), which has 501 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00001398 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Aplastic Anemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant
ACTIVE NOT RECRUITING · Phase 1
-
Unrelated Cord Blood Transplant Plus a Haplo-Identical (Half-Matched), T-Cell Depleted Stem Transplant From a Related Donor for Subjects With High Risk Malignancies
COMPLETED · Phase 1
-
Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization
COMPLETED · Phase 1
-
Let's Get REAL: Family Health Communication Tool in Pediatric Stem Cell Transplant and Cellular Therapy
RECRUITING · NA
-
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
RECRUITING · Phase 2
-
Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
RECRUITING · Early Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.